It’s been moving for years...... DOWN! And will continue so until it goes dark! Just like all of the rest of the kons delivered by Konman Koos!

A legal Kon from Koos and a cheap fraudster. Wish people would have seen it without flushing their $ down the Kamode, including a good friend who asked me to look into this Kon after it was to late.

Did you know that once Konman Koo's past Kons
crashed to the teens, the worthless paper never
recovered. Sayonara to this Kon and onto the next
one!

Hoping for a dead cat bounce so you can get out and cut that loss to something more tolerable. KonnanKoos has made a lot of people sick to their stomachs keeping his lifestyle funded at other peopke’s expense. He’s good at it!

“Anybody know what's going on with the Nerf?”

NERF will have to wait in line. The market is still waiting on the promises and PH 1 results of HemaX. What’s it been, a few years now?

Konman Koos makes a lot of investors look silly. And I imagine, pretty pis’t off!

Conversation?!? PPS is the bottom line to investing. Conversation LOL good luck making $$$ on talk

How can commentary on RGBP that months ago was $.03 cents and now is $.0025 be deflection? It seems to me, ignoring RGBP’s almost -100% YOY collapse is the ultimate deflection.

"There are trolls on this board."

And there are also Blather Breathers that pretend they are independent thinkers, just give the middle a chance.

To make a statement that RGBP could fail or succeed is ludicrous. Implication: there is a 50-50 chance.

Any person that has traded for a minimum of time can look at

1- Balance Sheet (Fundamentals): RGBP is insolvent

2- Price Action (Technicals) RGBP is approaching -100% YOY.

3- Management (Momentum): RGBP's mgm't has been in the game for about a decade and failed at every step. More importantly, this management has failed investors at every step.

4- Patents (Contrarian): OK.... they have patents like so many before, HemaX, right. Of the current crop, Lilly offered them a librarian card (speaks for itself). Also if you have the homework done, you would see there are well over 150 ongoing FDA current trials in this particular field. These trials are being done by big pharma, other pharma with partnerships in place, and small bio-techs with financing in place.

It's almost delusional to think that RGBP can overcome even one the above elements...... oooops, IMO that is not their mission. It is a PR company designed to keep investors sending their $ so Konman Koos can keep that $300K yearly salary....not based on one product or sale; just his pr's

"Fake Wall"

RGBP is down -96.14% YOY

RGBP is Fake, with its Fake scientific hypothesis! Long Live HemaX and dCellVac in the universe PR Archives with NERF soon to join...

“Regen supposedly.......”

Is the implication that RGBP and Koos purpotrated another misleading PR Con?

Komnan Koos, really?

"SUPER MEGA!" lol

RGBP was said to be "Mega" at 3 cents

RGBP, now we are told, is "Super Mega" at 1/2 cent

Ya Right. GLTA LONGS because you will need it at trip zeros

Agreed..... .0001’s next up

IMO you are absolutely on target with the 1.5 billion shares for RGBP! You have the talent in that RGBP calculation.

Koos education has been discussed repeatedly....and has nothing to do with anything.

RGBP is just one part of the OTC Koosglomerate shell that generates nothing but a $300K a year pay check for himself. NO PRODUCTS.... NO PHASE TRIALS.... Just PR's to generate enough Kooslaid drinking investors to keep his paycheck coming..... For over 10 years now!

RGBP is a simple transfer program.... investors $ to Koos wallet.

It should be assumed a KoosKon until he manages to actually bring a product to market or even completes a phase trial......

SEE RGBP HemaX: FDA actually green lighted phase 1 trial, and RGBP dropped the product and moved on to the current Kon.

“What? Could you repeat that?”

RGBP is down -94.57% over one year as of yesterday.

Of course any realist verbalizing these catastrophic results would be repeating themselves.

Only the Kooslaid Drinkers pump this Kooskon.

It’s Broken defined: -94.57% (real investors define a broken equity as -37.5%)

It only works for Konman Koos cashing about $300K salary each year from his hollow OTC Konglomerate. He loves his PR marks all the way to the bank as his long history including RGBP has NEVER produced one product, never sold one product, never completed phase 3, never completed phase 2, never completed phase 1, and has never even attempted starting phase 1 even after given the green light to do so...

RGBP same old Kon

"Tis the season"

Just a few weeks ago, RGBP:

Tis the season for to the moon PR's and price explosion.

You have to give credit to how good RGBP's Konman is....

When is the last time you saw RGBP address the reality of
their insolvent balance sheet? What happened to HemaX
and the others? What comes after the dilution? Toxic Funding?

Reality just doesn't matter, here. Just keep'm buying the stock

purely a wild guess:

to early for a R/S.

You were smart enough to buy RGBP!

How’s that working out for you?

Grounded and well stated

“....no dummy....”

Do not forget to add these cons from RGBP’s CEO Koos’s past.
All investors lost their $’s on them which will happen with RGBP.
Mega-Science of that time!

June 29, 2006--Bio-Matrix Scientific Group, Inc., a Delaware corporation (Pink Sheets:BMXP), a biotechnology company focused on stem cell cryogenics and disposable stem cell / tissue transfer instruments,

June 29, 2009
Bio-Matrix Scientific Group, Inc. (OTCBB:BMSN), a San Diego-based biotechnology company, announced today the launch of a national marketing program aimed at hospitals in need of storing umbilical cord blood specimens for future transplantation.

Prediction?

do you have any doubt RGBP is going the way of BMSN?

BTW, your post was
Hillarious, if not for all those guys who lost $ on the KoosKon including a personal friend who donated $12K to the Konman's lifestyle.

The implied message is?

"Lilly's Open Innovation Drug Discovery Program is visionary," said Harry Lander, Ph.D., MBA, president and chief scientific officer of Regen BioPharma, Inc. "They understand the value of partnering in a confidential manner with smaller entities that may have intellectual property that aligns with their product goals.”

Mega Science = .0069

I got this old and successful by not investing in the lIkes of RGBP and CEO Konman, allowing me to hire a roomful of people to look at these Kons (RGBP, BMSN, ENTB, and that OTC comglomerate)
with support staff as well. Get your facts straight Koolaids drinker.

The OTC market has spoken on RGBP .0075

The OTC market doesn’t care about Mega Hypothesis, Opinions or Penny Stock Poets.

RGBP’s balance sheet speaks for itself: Insolvent! PR’s arent going to change that. Only toxic funding or dilution.

RGBP’s CEO’s track record speaks for itself. Nothing! Except cashing $350K each year for a heck of a long time using investor’s $$$$$

NOT one sale. NOT even one ph 1 trial.

Good Luck to you if you drank the Kooslaid. Beware if you have stumbled across this one.

ATM's Pay

It seems the RGBP ATM pays for the astute:

1- Shorts getting paid for their investment against the con

2- RGBP and Konman Koos getting the ponzi payoff.

The longs have lost $ a year ago, a month ago, a week ago,
any yesterday's buyers. Not very astute, right?

Nice Deflection

Reality: Price under $0.01

Anybody buying last week is underwater
Anybody buying last month is underwater
Anybody buying last year is underwater

HemaX was green lighted for Ph 1 in Dec 2015.

Nearly 3 years later, they have not started the trials. Have you ever heard of a biopharma getting the green light and not starting trials?

Why?

Could be that the company is insolvent?

Could be they are completely incompetent? ( i personally think not.... he's been cashing $300K every year for a long time )

Could be that the company shelved it as it was only a stock ploy?

or in the words of the well paid CEO:

"We were delighted that our licensees initiated this trial and that Regen could support them. It is gratifying to see that HemaXellerate may have some benefit to these patients," said Dr. David Koos, CEO. Tijuana, Mexico

"MAY HAVE SOME BENEFIT" = They know/knew it doesn't work.

Keep in mind, the entire self-stated premise of RGBP was to protect HemaX from hostile takeovers or make great deals down the road: A TOP PRIORITY.
IMO RGBP was created because BMSN was no longer a viable investable con.

"this would be exactly 3 weeks from last release and would keep the momentum going."

What? is this a joke?

RGBP's last 21 days is absolutely the opposite definition of "momentum."

Here's how it is NOT suppose to look!
RGBP's numbers:

10/25/18 0.0078 3,174,640
10/20/18 0.0077 5,426,500
10/23/18 0.0097 1,993,500
10/22/18 0.0086 1,046,400
10/19/18 0.0088 1,521,400
10/18/18 0.0089 4,128,700
10/17/18 0.0115 3,750,400
10/16/18 0.0095 3,983,000
10/15/18 0.0110 901,900
10/14/18 0.0131 528,600
10/11/18 0.0140 1,093,000
10/10/18 0.0115 579,100
10/09/18 0.0122 772,000
10/08/18 0.0125 1,354,100
10/05/18 0.0140 2,258,500
10/04/18 0.0109 1,053,100
10/03/18 0.0110 509,200
10/02/18 0.0110 771,100
10/01/18 0.0112 1,488,800
09/28/18 0.0118 2,810,900
09/27/18 0.0129 1,179,700
09/26/18 0.0120 758,100
09/25/18 0.0120 1,472,300
09/20/18 0.0140 3,241,900
09/21/18 0.0180 6,660,500
09/20/18 0.0125 572,500
09/19/18 0.0158 695,600
09/18/18 0.0125 346,300
09/17/18 0.0170 284,200
09/10/18 0.0175 342,800

Dr. Smith: "The sky is falling Captain Robinson. We're doomed, we're all doomed!"
_____________________________________________________________________________________

An interesting RGBP analysis given that there has been implied criticism of "ROFL"
being used on the RGBP board, not since the 1990's

Of course, the KoosLaid Drinkers see nothing but sunny skies for RGBP.

IF you bought RGBP in these timeframes, you are underwater (no sunny side there)

1-Month -48.95%
3-Month -62.40%
6-Month -73.13%
YTD -86.14%
52-Week -92.40%

in the professional world, equities are generally considered broken at -37.5%

THANK YOU For reinforcing the naysayer's claim that RGBP is nothing more than pump and dump. And, thank you for being honest that your buys attempt to time the pump. So much for mega-science.

1- Your theory as stated is applied to the OTC or bio's in general

2- RGBP: Are you guessing that theory applies to RGBP?

3- RGBP was here before, and the pump did not materialize.

4- RGBP's management has been here before with multiple stuff within other OTC entities and none of it materialized

5- Chart Koosland after -90% yoy losses and I have yet to see a pump of any breadth. There is a watershed moment and when this management ends up crossing that event, it always ends up at trips.

6- That's not to say that they will maintain their 100% streak and that eventually he will find one that does pump. Hope so for the hard workers & their $$$$ out there. But not with our $$$.

7- IMO the opportunity here was the RGBP spinoff, years ago. Buying in to get free RGBP shares was the big money maker. Then unloading it ASAP. It's been nothing but their typical track record since .25 cent spinoff.

Every RGBP long that purchased before October is pretty much underwater, a losing strategy.

RGBP -90% yoy.... next stop -100% yoy

Mega-Technical Investing 101: -38.2% = a broken stock

Mega-Fundamental Investing 101: An insolvent balance = An un-investable stock.

RGBP

FROM THAT SAME LINK https://www.volumebot.com/?s=rgbp
"RGBPShort Volume Indicator: [I]
Slightly Bearish - Pay More Attention to Technicals & Fundamentals"

YES, Trying to alert to the con is "going to any lengths" to deceive you:

http://shortsqueeze.com/?symbol=RGBP&submit=Short+Quote%E2%84%A2

http://otce.finra.org/ESI

It's not the evil shorts. The 90+% decline in RGBP is the result of Konman Koos.

the last time i asked, the short squeeze ratio was 0.01

has it changed?

poetic justice

I had them pull up the last 12 months on this one: -90.21%
It’s at the bottom of our OTC spread sheet. Hopefully
the rational can see that the market is speaking loud and clear.

Btw, nobody in my office is spending their hard earned $$$ on RGBP
or KonmanKoos. Everybody that has bought in the last 12 months is UNDER WATER!
And/or writing silly poems of hope about RGBP.

2018-09-14
0.0144
2018-08-03
0.0206
2018-07-12
0.0267
2018-06-06
0.0270
2018-05-04
0.0299
2018-04-02
0.0399
2018-03-08
0.0430
2018-02-01
0.0499
2017-12-04
0.0815
2017-11-20
0.0910

All positive assumptions and acts for RGBP. Can you state any RGBP outcomes based on negative assumptions? Or based upon RGBP's past actions?

RGBP & IBS, "Yah Right"

There are over 100 "IBS" trials, enrollments or studies already in progress. An insolvent RGBP with unproven management is going to compete with these guys as far as resources and/or funding?
"Yah Right!"

Below is a list of ongoing IBS trials that RGBP has no chance of competing with. BTW, did RGBP and Konman mention how far advanced the competition is in his "IBS" RGBP PR? or did he just create excitement or false hope for the astute masses?

IBS Trial Identifier TX148387
ACRC Trials Phase 4
IBS Trial Identifier TX147617
Precision Clinical Research, LLC N/A
IBS Trial Identifier TX147617
West Michigan Clinical Research Center Phase 3
IBS Trial Identifier TX145440
E Squared Research, Inc. Phase 3
IBS Trial Identifier TX143109
IMA Research Phase 3
IBS Trial Identifier TX141569
n/a Phase 3
IBS Trial Identifier TX140883
Boston Clinical Trials Phase 3
IBS Trial Identifier TX137299
Washington University - Center for Clinical Studies Trials: Enrolling
IBS Trial Identifier TX136739
Advanced Pharma CR Phase 3
IBS Trial Identifier TX206866
Diagnostics Research Group Trials: Enrolling
IBS Trial Identifier NCT02837783
Wythenshawe, United Kingdom Phase 4
IBS Trial Identifier NCT03225261
Maastricht University Medical Center Netherlands Phase 4
IBS Trial Identifier NCT02847481
Beth Israel Deaconess Medical Center Phase 1
IBS-D for Women TX137845
Beacon Clinical Research Phase 3

as well as 100+ more RFBP competitors already in the game. BTW, I thought NERF was for cancer?

listen, I hope RGBP goes to a nickel or dime or quarter, so you guys can ring it up.

IMO, which is different from the long's is based on RGBP's balance sheet and Portfolio Track Record:
Trips on the way.

This PR Sell Trigger?????

If checkpoint theory is revolutionary, and I do not doubt it, then:

1 - Why has not Eli Lilly bought out RGBP?

2 - If as RGBP's PR stated ("If our stuff pans out"); then what does Lilly know about NERF?

3 - With What Lilly does know, Why did they not make a major financial investment in Koos?

4 - Is Lilly's lack of RGBP investment interest telling this board that they have better candidates with better NERF's? Or does Lilly have it's own super secret NERF program?

IMO You could take a high risk flyer on RGBP, if their balance sheet justified it, track record justified it, and solid management. But, the reality is RGBP is insolvent and exists in Koosland = OTC Koosklomerate.

Bottom line, and indirect PR within same technology class is not investable.

RGBP Patience? RGBP Mega Science? Or Just another transition to the next iteration?

Bio Matrix Scientific : Regen BioPharma Provides Update on dCellVax Breast Cancer Immunotherapy
08/01/2014 | 10:00am EDT

SAN DIEGO, CA--(Marketwired - Aug 1, 2014) - Regen BioPharma Inc. (a company majority owned by Bio-Matrix Scientific Group Inc.) (PINKSHEETS: BMSN) reported today on progress in development of dCellVax, a "therapeutic cancer vaccine" which stimulates the immune system of patients to selectively kill tumors.

Thomas Ichim, PhD, Chief Scientific Officer of Regen BioPharma, stated, "We are pleased to announce that Regen BioPharma has successfully achieved silencing of the IDO gene in human dendritic cells, which is a major step forward in development of our Investigational New Drug (IND) application to the FDA." He further noted that "Not only is this a significant milestone, but this provides additional trade secrets in our production methodology with the possibility of filing new patents on the optimized methodology and reagents we have developed."

The scientific foundation of dCellVax was developed by Dr. Wei-Ping Min, Professor at the University of Western Ontario. The patent related to this therapy, US patent # 8,389,708, was previously assigned to the company by Dr. Min. Dr. Min effectively used dendritic cells (DC) that are "gene silenced" to induce regression of breast cancer in animal models. The company also entered into a license agreement with Benitec Biopharma covering specific uses of their platform gene silencing technology for use in dCellVax. Dr. Min's animal efficacy data was previously published in peer-reviewed journal articles (1, 2).

The dCellVax therapeutic product is based on extracting blood from patients, growing a specialized type of immune cell from the blood called the "dendritic cell" and then subsequently genetically modifying the dendritic cell to become resistant to cancer's immune suppressive activity. It is known that cancer modifies the immune system by producing proteins which result in immune suppression. One such protein which cancer stimulates is an enzyme, indolamine 2,3 deoxygenase (IDO), which cancer turns on in dendritic cells. While dendritic cells are usually immune stimulators, dendritic cells found in cancer patients suppress the immune system as a result of expressing IDO. By administering dendritic cells that are silenced for IDO, it has been demonstrated that substantially enhanced antitumor responses may be stimulated.

Although Regen BioPharma and Dr. Wei-Ping Min have previously published in the area of gene silencing, all work has been performed in animal studies. These are the first experiments in which human cells were utilized in a manner similar to which will be filed with the FDA. "We are optimistic that this data will lead to advancement of dCellVax into clinical trials," said David Koos, PhD, Chairman and CEO of Regen BioPharma. "The smooth translation of this university acquired intellectual property into a commercial setting further supports the Regen BioPharma model of rapidly advancing patents that are sitting un-noticed in the technology transfer offices of universities."

About Regen BioPharma Inc.:

Regen BioPharma Inc., a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN), is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is focused on developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer. For more information refer to the company's website http://www.regenbiopharma.com/

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

References
(1) Zheng et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer. 2013 Feb 15;132(4):967-77).

Sage Advise on this loser

Busted. Confession: Wanted to buy 100 shares but RGBPP to expensive.